HLS Therapeutics (TSX:HLS) Cyclically Adjusted Revenue per Share: C$4.02 (As of Mar. 2026)


TSX:HLS HLS Therapeutics Inc TSX:HLS
67 GF Score
Price C$4.30
GF Value C$4.51
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is HLS Therapeutics Cyclically Adjusted Revenue per Share?

HLS Therapeutics TSX:HLS 67 Cyclically Adjusted Revenue per Share is C$4.02 as of Mar. 2026. GuruFocus rates TSX:HLS with a GF Score™ of 67/100 and a GF Value™ of C$4.51 (Fairly Valued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

HLS Therapeutics's adjusted revenue per share for the three months ended in Mar. 2026 was C$0.564. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is C$4.02 for the trailing ten years ended in Mar. 2026.

During the past 12 months, HLS Therapeutics's average Cyclically Adjusted Revenue Growth Rate was -2.40% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -4.70% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was -4.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of HLS Therapeutics was 8.40% per year. The lowest was -16.70% per year. And the median was -1.40% per year.

As of today (2026-07-08), HLS Therapeutics's current stock price is C$4.30. HLS Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was C$4.02. HLS Therapeutics's Cyclically Adjusted PS Ratio of today is 1.07.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of HLS Therapeutics was 4.57. The lowest was 0.46. And the median was 1.93.


HLS Therapeutics  (TSX:HLS) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

HLS Therapeutics's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=4.30/4.02
=1.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of HLS Therapeutics was 4.57. The lowest was 0.46. And the median was 1.93.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


HLS Therapeutics Cyclically Adjusted Revenue per Share Related Terms


HLS Therapeutics Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for HLS Therapeutics's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

HLS Therapeutics Cyclically Adjusted Revenue per Share Chart

HLS Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.96 4.65 4.46 4.13 4.02

HLS Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.12 4.09 4.05 4.02 4.02

TSX:HLS vs ZTS, UTHR: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, HLS Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HLS Therapeutics Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, HLS Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where HLS Therapeutics's Cyclically Adjusted PS Ratio falls into.


TSX:HLS
67GF Score
HLS Therapeutics Inc TSX:HLS
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

HLS Therapeutics Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, HLS Therapeutics's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.564/132.2623*132.2623
=0.564

Current CPI (Mar. 2026) = 132.2623.

HLS Therapeutics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.000 102.002 0.000
201609 0.000 101.765 0.000
201612 5.553 101.449 7.240
201703 0.000 102.634 0.000
201706 0.000 103.029 0.000
201709 0.000 103.345 0.000
201712 3.495 103.345 4.473
201803 0.662 105.004 0.834
201806 0.780 105.557 0.977
201809 0.729 105.636 0.913
201812 0.820 105.399 1.029
201903 0.645 106.979 0.797
201906 0.636 107.690 0.781
201909 0.578 107.611 0.710
201912 0.594 107.769 0.729
202003 0.546 107.927 0.669
202006 0.538 108.401 0.656
202009 0.547 108.164 0.669
202012 0.665 108.559 0.810
202103 0.564 110.298 0.676
202106 0.570 111.720 0.675
202109 0.590 112.905 0.691
202112 0.619 113.774 0.720
202203 0.568 117.646 0.639
202206 0.613 120.806 0.671
202209 0.646 120.648 0.708
202212 0.658 120.964 0.719
202303 0.624 122.702 0.673
202306 0.674 124.203 0.718
202309 0.673 125.230 0.711
202312 0.663 125.072 0.701
202403 0.529 126.258 0.554
202406 0.625 127.522 0.648
202409 0.600 127.285 0.623
202412 0.696 127.364 0.723
202503 0.570 129.181 0.584
202506 0.612 129.892 0.623
202509 0.595 130.287 0.604
202512 0.670 130.366 0.680
202603 0.564 132.262 0.564

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of C$4.02 mean?
HLS Therapeutics (TSX:HLS) has a Cyclically Adjusted Revenue per Share of C$4.02 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on HLS Therapeutics and its competitors.
Is HLS Therapeutics' Cyclically Adjusted Revenue per Share too high?
HLS Therapeutics' current Cyclically Adjusted Revenue per Share is C$4.02. Overall, HLS Therapeutics has a GF Score™ of 67/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does HLS Therapeutics' Cyclically Adjusted Revenue per Share compare to ZTS and UTHR?
HLS Therapeutics' Cyclically Adjusted Revenue per Share of C$4.02 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on HLS Therapeutics and its competitors. HLS Therapeutics's current Cyclically Adjusted Revenue per Share is C$4.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HLS Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, HLS Therapeutics (TSX:HLS) is currently considered Fairly Valued. The stock's GF Value™ is C$4.51, compared to a current price of C$4.30 — trading 4.7% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is C$4.02. HLS Therapeutics' overall GF Score™ is 67/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For HLS Therapeutics (TSX:HLS), the current Cyclically Adjusted Revenue per Share is C$4.02 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is HLS Therapeutics (TSX:HLS) Overvalued in 2026?

Based on GuruFocus' analysis, HLS Therapeutics stock appears to be undervalued. The current stock price of C$4.30 is trading 4.7% below its estimated GF Value™ of C$4.51. GuruFocus considers HLS Therapeutics to be Fairly Valued.

Key valuation signals for TSX:HLS:

  • Cyclically Adjusted Revenue per Share: C$4.02
  • GF Value™: C$4.51 vs. price of C$4.30 (4.7% below fair value)
  • GF Score™: 67/100 with 4 warning signs

No single metric tells the full story. See the TSX:HLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


HLS Therapeutics Business Description

Other Exchanges HLTRF:USA74D:Germany
Address 10 Carlson Court, Suite 701, Etobicoke, Toronto, ON, CAN, M9W 6L2
HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company's products include Clozaril, Vascepa, CSAN Pronto, and others. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, the United States, and the Rest of world, with the majority of its revenue generated from Canada.
67GF Score

Get the complete analysis for TSX:HLS

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$4.30
Price
C$4.51
GF Value